The composition and structure of gut microbiota plays an important role in obesity induced by a high-fat diet (HFD) and related metabolic syndrome (MetS).
The similarity evaluation of skull data is a research work of great significance and has been widely used in forensic, archaeology, and other fields. In this paper, we propose a 3D skull similarity evaluation method based on Siamese Network. Firstly, the original 3D skull data are mapped onto 2D depth images, which maintains the original information of the 3D data to the greatest extent. Then, we introduce the residual structure into the Siamese network to extract the main features of any pair of skull depth image data and map it to a new space for representation. Finally, a mapping function is proposed to calculate a reasonable similarity value of 0-1 between the two input skull data through the sigmoid layer. We conducted objective experiments on 3D skull models and compared them with the subjective skull similarity. The experimental results show that the 3D skull similarity evaluation method based on Siamese network with residual structure can effectively evaluate the similarity of skulls. The results are basically consistent with people's subjective evaluation, providing an effective direction for craniofacial reconstruction and identification.
Hepatocellular carcinoma (HCC) has a high degree of malignancy and poor prognosis. Treatment options for patients with advanced HCC are limited. There is currently no evidence to approve the accumulation of targeted therapies for HCC to support the inhibition of the PI3K/Akt/mTOR signaling pathway as an effective therapeutic strategy. We report on a patient with advanced HCC carrying the TSC1 gene mutation who responded well to the mammalian target of rapamycin inhibitor everolimus. Computed tomography revealed tumor shrinkage and maintenance of partial remission after everolimus treatment for >12.3 months. To the best of our knowledge, this is the first clinical case report showing benefit from everolimus treatment in HCC patients with TSC1 gene mutations. Therefore, everolimus may be used as a potential targeted therapy for HCC with TSC1 gene mutation.